Objective:
To provide guidance on coding, billing, and reimbursement for photobiomodulation (PBM) treatment of intermediate dry age-related macular degeneration (AMD), highlighting its significance as a novel treatment option.
Key Findings:
- PBM has shown potential to improve visual function in patients with intermediate dry AMD, offering a new treatment avenue.
- Medicare does not cover facility fees for PBM, and reimbursement is primarily for services performed by qualified healthcare professionals, impacting patient access.
- CPT code 0936T was introduced for PBM, but other related codes are not applicable, limiting billing options.
- State laws vary regarding the scope of practice for healthcare providers performing PBM, affecting who can administer the treatment.
Interpretation:
The introduction of PBM offers a new treatment avenue for AMD, but providers must navigate complex billing and regulatory landscapes to ensure proper reimbursement, which is crucial for patient access.
Limitations:
- Variability in state laws may affect the ability of certain healthcare professionals to perform PBM, complicating practice management.
- Medicare reimbursement policies may not cover all aspects of PBM treatment, limiting financial viability for practices.
Conclusion:
PBM represents a promising treatment for AMD, but healthcare providers must be diligent in understanding coding and reimbursement processes to optimize patient care and ensure access.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.